Device Trial Radar · NCT05399537
Safety Evaluation of Prismocitrate 18 in Patients Receiving CRRT
Last checked: Nov 20, 2026Latest source record: Oct 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
40
Planned (sponsor's estimate)
Start
Jul 12, 2024
Primary completion
Jan 2027
Study completion Jan 2027
Sponsor
- Lead sponsor
- Vantive Health LLCNot on our public-company list
- Sponsor type
- Industry
- Collaborators
- Baxter Healthcare Corporation
- First posted
- Jun 1, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated device
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Prismocitrate 18 is a continuous renal replacement therapy (CRRT) solution to be used as a renal replacement solution and as an anticoagulant to prevent blood clotting in the extracorporeal circuit. The delivery of CRRT therapy is provided by the PrisMax System which includes regional citrate anticoagulation (RCA) software to facilitate citrate and calcium compensation prescription. The objectives of this study are: 1) to confirm the safety of Prismocitrate 18 in patients receiving CRRT using continuous venovenous hemodiafiltration (CVVHDF) or continuous venovenous hemofiltration (CVVH) and 2) to observe that the software and interface for the PrisMax System Version 3.x with calcium line accessory allows for implementation of regional citrate anticoagulation (RCA) (citrate and calcium dosing) during CRRT with Prismocitrate 18 and intended prescription. The study period of the patient's CRRT will be up to 10 days.
Conditions
- Regional Citrate Anticoagulation (RCA)
- Continuous Renal Replacement Therapy (CRRT)
- Acute Kidney Injury (AKI)
Interventions
Prismocitrate 18Drug
Prismocitrate 18 solution (investigational drug) will be used in pre-dilution mode only; the rate of administration depends on the targeted citrate dose and the prescribed flow rate. The pre-filter infusion rate of Prismocitrate 18 solution will be indexed to the blood flow rate (BFR) to achieve a target blood citrate concentration of 3 mmol/L of blood. The flow rate for the anticoagulation of the extracorporeal circuit will be titrated to achieve a post-filter concentration of iCa of 0.25 to 0.35 mmol/L.
PrisMax System Version 3.x with calcium line accessoryDevice
The RCA software on PrisMax System Version 3.x with calcium line accessory (investigational device) will be enabled to carefully guide the health practitioner for citrate dosing and calcium compensation.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with symptomatic hypocalcemia related to Prismocitrate 18 administrationTime frame: Day 1 up to Day 10
2 more outcomes with a free account
Locations
14 sites in 1 country. Site status is shown where the registry gives one.
University of Alabama at Birmingham/UAB
Birmingham, Alabama · Recruiting
13 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.